Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML).

Literature DB >> 16790588

More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML).

Rajko Kusec, Ozren Jaksic, Slobodanka Ostojic, Ika Kardum-Skelin, Radovan Vrhovac, Branimir Jaksic.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2006 PMID： 16790588 DOI： 10.1182/blood-2005-12-5128

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

15 in total

Review 1. Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors: Muneera Al-Hussaini; John F DiPersio
Journal: Expert Rev Hematol Date: 2014-08 Impact factor: 2.929

2. Impact of FLT3-ITD length on prognosis of acute myeloid leukemia.

Authors: Song-Bai Liu; Hao-Jie Dong; Xie-Bing Bao; Qiao-Cheng Qiu; Hong-Zhi Li; Hong-Jie Shen; Zi-Xuan Ding; Chao Wang; Xiao-Ling Chu; Jing-Qiu Yu; Tao Tao; Zheng Li; Xiao-Wen Tang; Su-Ning Chen; De-Pei Wu; Ling Li; Sheng-Li Xue
Journal: Haematologica Date: 2018-08-03 Impact factor: 9.941

3. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors: Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544

Review 4. FLT3-ITD and its current role in acute myeloid leukaemia.

Authors: Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal: Med Oncol Date: 2017-05-03 Impact factor: 3.064

5. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.

Authors: Harshabad Singh; Lillian L Werner; Salma Asali; Daniel J DeAngelo; Karen K Ballen; Philip C Amrein; Martha Wadleigh; Ilene Galinsky; Brian Wolpin; Joseph Pidala; Donna S Neuberg; Edward A Fox; Richard M Stone; Eyal C Attar
Journal: Am J Hematol Date: 2011-07 Impact factor: 10.047

More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML).

Review 1. Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

2. Impact of FLT3-ITD length on prognosis of acute myeloid leukemia.

3. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Review 4. FLT3-ITD and its current role in acute myeloid leukaemia.

5. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.

6. Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study.

Review 7. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.

Review 8. Clinical implications of molecular markers in acute myeloid leukemia.

Review 9. The Biology and Targeting of FLT3 in Pediatric Leukemia.

10. FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others.